ATE291436T2 - Flüssige arzneizubereitung enthaltend ein erythropoietin derivat - Google Patents

Flüssige arzneizubereitung enthaltend ein erythropoietin derivat Download PDF

Info

Publication number
ATE291436T2
ATE291436T2 AT01943331T AT01943331T ATE291436T2 AT E291436 T2 ATE291436 T2 AT E291436T2 AT 01943331 T AT01943331 T AT 01943331T AT 01943331 T AT01943331 T AT 01943331T AT E291436 T2 ATE291436 T2 AT E291436T2
Authority
AT
Austria
Prior art keywords
preparation containing
medicinal preparation
liquid medicinal
erythropoietin derivative
erythropoietin
Prior art date
Application number
AT01943331T
Other languages
English (en)
Inventor
Apollon Papadimitriou
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8168722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE291436(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE291436T2 publication Critical patent/ATE291436T2/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01943331T 2000-05-15 2001-05-08 Flüssige arzneizubereitung enthaltend ein erythropoietin derivat ATE291436T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00110355 2000-05-15
PCT/EP2001/005187 WO2001087329A1 (en) 2000-05-15 2001-05-08 Liquid pharmaceutical composition containing an erythropoietin derivate

Publications (1)

Publication Number Publication Date
ATE291436T2 true ATE291436T2 (de) 2005-04-15

Family

ID=8168722

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01943331T ATE291436T2 (de) 2000-05-15 2001-05-08 Flüssige arzneizubereitung enthaltend ein erythropoietin derivat

Country Status (35)

Country Link
US (2) US7169754B2 (de)
EP (2) EP1525889A1 (de)
JP (1) JP3967594B2 (de)
KR (3) KR20050121762A (de)
CN (1) CN1309416C (de)
AR (2) AR035034A1 (de)
AT (1) ATE291436T2 (de)
AU (1) AU784091B2 (de)
BR (1) BRPI0110914B8 (de)
CA (1) CA2408685C (de)
CZ (1) CZ304855B6 (de)
DE (1) DE60109625T3 (de)
DK (1) DK1311285T4 (de)
EC (2) ECSP024352A (de)
ES (1) ES2237574T5 (de)
HR (1) HRP20020880B1 (de)
HU (1) HU230874B1 (de)
IL (2) IL152659A0 (de)
JO (1) JO3404B1 (de)
MA (1) MA26901A1 (de)
ME (1) ME00673B (de)
MX (1) MXPA02011303A (de)
MY (1) MY128654A (de)
NO (1) NO330934B1 (de)
NZ (1) NZ522030A (de)
PE (1) PE20020050A1 (de)
PL (1) PL219131B1 (de)
PT (1) PT1311285E (de)
RS (1) RS51292B (de)
RU (1) RU2281116C2 (de)
SI (1) SI1311285T1 (de)
TW (2) TWI288643B (de)
UY (1) UY26704A1 (de)
WO (1) WO2001087329A1 (de)
ZA (1) ZA200208500B (de)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5545553A (en) * 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US7304150B1 (en) * 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
AU2001261024A1 (en) 2000-04-12 2001-10-30 Delta Biotechnology Limited Albumin fusion proteins
PT1311285E (pt) 2000-05-15 2005-06-30 Hoffmann La Roche Composicao farmaceutica liquida contendo um derivado de eritropoietina
JP4656814B2 (ja) * 2000-12-20 2011-03-23 エフ．ホフマン−ラ ロシュ アーゲー エリスロポエチンコンジュゲート
EP1345628B1 (de) * 2000-12-20 2011-04-13 F. Hoffmann-La Roche AG Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
FR2823220B1 (fr) * 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
AU2002310122A1 (en) * 2001-05-25 2002-12-09 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
JP2003152145A (ja) * 2001-08-31 2003-05-23 Sumitomo Electric Ind Ltd 半導体放熱用基板とその製造方法及びパッケージ
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7795210B2 (en) * 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7399613B2 (en) * 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7179617B2 (en) * 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
EP2277910A1 (de) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin Fusionsproteine
EP1463752A4 (de) * 2001-12-21 2005-07-13 Human Genome Sciences Inc Albuminfusionsproteine
DE60336555D1 (de) * 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
SI21258A (sl) * 2002-07-17 2004-02-29 LEK farmacevtska dru�ba d.d. Stabilni farmacevtski pripravek, ki vsebuje eritropoietin in poloksamerni poliol
US7459435B2 (en) * 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
EP1545586A4 (de) * 2002-09-09 2007-09-26 Warren Pharmaceuticals Inc Erythropoetine mit langzeitwirkung zur aufrechterhaltung der gewebeschutzaktivität von endogenem erythropoetin
US7470779B2 (en) * 2002-09-20 2008-12-30 Pfizer Inc. Process for decreasing aggregate levels of pegylated protein
US7459436B2 (en) * 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
EP1594530A4 (de) 2003-01-22 2006-10-11 Human Genome Sciences Inc Albuminfusionsproteine
EP1608688B1 (de) * 2003-03-14 2013-02-27 BioGeneriX AG Verzweigte wasserlösliche polymere und konjugate davon
EP1613261A4 (de) * 2003-04-09 2011-01-26 Novo Nordisk As Intrazelluläre bildung von peptidkonjugaten
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
AU2004240553A1 (en) * 2003-05-09 2004-12-02 Neose Technologies, Inc. Compositions and methods for the preparation of human growth hormone glycosylation mutants
NZ543934A (en) * 2003-05-12 2008-06-30 Affymax Inc Novel spacer moiety for poly (ethylene glycol)-modified peptide-based compounds
ATE478093T1 (de) * 2003-05-12 2010-09-15 Affymax Inc Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen
NZ543935A (en) * 2003-05-12 2008-06-30 Affymax Inc Peptides that bind to the erythropoietin receptor
NZ543905A (en) 2003-05-12 2008-07-31 Affymax Inc Peptides that bind to the erythropoietin receptor
ATE553747T1 (de) 2003-06-10 2012-05-15 Lg Life Sciences Ltd Stabile wässrige lösung von human-erythropoietin, die kein serumalbumin enthält
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US8633157B2 (en) * 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
ES2445948T3 (es) * 2003-11-24 2014-03-06 Ratiopharm Gmbh Eritropoyetina glicopegilada
US20080305992A1 (en) * 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
AU2004296855B2 (en) * 2003-12-03 2011-01-06 Ratiopharm Gmbh Glycopegylated Granulocyte Colony Stimulating Factor
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US20080318850A1 (en) * 2003-12-03 2008-12-25 Neose Technologies, Inc. Glycopegylated Factor Ix
SI1696947T1 (sl) 2003-12-19 2014-05-30 F. Hoffmann-La Roche Ag Uporaba eritropoetina pri zdravljenju motenj porazdelitve železa pri kroničnih vnetnih črevesnih boleznih
NZ548123A (en) * 2004-01-08 2010-05-28 Novo Nordisk As O-linked glycosylation of peptides
NZ548255A (en) * 2004-02-02 2010-10-29 Ambrx Inc Modified human interferon polypeptides and their uses
DE202004020676U1 (de) * 2004-03-10 2005-11-10 Bioceuticals Arzneimittel Ag Erythropoietin-Flüssigformulierung
WO2005089743A1 (ja) * 2004-03-19 2005-09-29 Ajinomoto Co., Inc. 腎性貧血治療剤
US20050282751A1 (en) * 2004-03-19 2005-12-22 Ajinomoto Co., Inc. Therapeutic agent for renal anemia
EA010889B1 (ru) * 2004-03-26 2008-12-30 Янссен Фармацевтика Н.В. Комбинированная схема дозирования эритропоэтина
AR049580A1 (es) * 2004-07-07 2006-08-16 Lundbeck & Co As H Epo carbamilada y metodo para su produccion
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
US20090292110A1 (en) * 2004-07-23 2009-11-26 Defrees Shawn Enzymatic modification of glycopeptides
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US20060029551A1 (en) * 2004-08-05 2006-02-09 Kui Liu Stable particle formulations of erythropoietin receptor agonists
WO2006031811A2 (en) * 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
EP2586456B1 (de) 2004-10-29 2016-01-20 ratiopharm GmbH Umformung und GlycoPEGylierung des Fibroblastenwachstumsfaktors (FGF)
JP2006137678A (ja) * 2004-11-10 2006-06-01 Shionogi & Co Ltd インターロイキン−２組成物
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006060148A2 (en) * 2004-11-11 2006-06-08 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
US20100009902A1 (en) * 2005-01-06 2010-01-14 Neose Technologies, Inc. Glycoconjugation Using Saccharyl Fragments
JP4951527B2 (ja) 2005-01-10 2012-06-13 バイオジェネリックス アーゲー 糖ｐｅｇ化顆粒球コロニー刺激因子
JP2008527980A (ja) * 2005-01-25 2008-07-31 アポロ ライフ サイエンシズ リミテッド 分子およびそのキメラ分子
EP1866427A4 (de) * 2005-03-30 2010-09-01 Novo Nordisk As Herstellungsverfahren zur produktion von in insektenzelllinien entstandenen peptiden
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20070037886A1 (en) * 2005-04-26 2007-02-15 Ajinomoto Co., Inc. Bone marrow erythroid progenitor cell(s) differentiation inducer
WO2006127910A2 (en) * 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
US20080255026A1 (en) * 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
US20110003744A1 (en) * 2005-05-25 2011-01-06 Novo Nordisk A/S Glycopegylated Erythropoietin Formulations
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7790679B2 (en) * 2005-08-05 2010-09-07 Amgen Inc. Pharmaceutical formulations
US20070105755A1 (en) * 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
AU2006280932A1 (en) * 2005-08-19 2007-02-22 Novo Nordisk A/S Glycopegylated factor VII and factor Vila
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
MX2008006626A (es) 2005-11-23 2008-09-24 Acceleron Pharma Inc Antagonistas de activin-actriia y usos para promover el crecimiento de huesos.
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CN101015684B (zh) * 2006-02-10 2011-08-24 华北制药集团新药研究开发有限责任公司 一种重组人红细胞生成素溶液制剂
EP1997505A4 (de) * 2006-03-22 2013-02-13 Chugai Pharmaceutical Co Ltd Zubereitung einer erythropoetinlösung
US20080248959A1 (en) * 2006-07-21 2008-10-09 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
KR20090046923A (ko) * 2006-08-04 2009-05-11 프로롱 파마슈티컬스, 인크. 수식된 에리스로포이에틴
JP2010505874A (ja) 2006-10-03 2010-02-25 ノヴォ ノルディスク アー／エス ポリペプチドコンジュゲートの精製方法
WO2008060780A2 (en) * 2006-10-04 2008-05-22 Novo Nordisk A/S Glycerol linked pegylated sugars and glycopeptides
US20080207487A1 (en) * 2006-11-02 2008-08-28 Neose Technologies, Inc. Manufacturing process for the production of polypeptides expressed in insect cell-lines
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
AU2008237411B2 (en) 2007-04-03 2013-10-03 Ratiopharm Gmbh Methods of treatment using glycopegylated G-CSF
US20090053167A1 (en) * 2007-05-14 2009-02-26 Neose Technologies, Inc. C-, S- and N-glycosylation of peptides
US20080286341A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered coated nicotine containing products
WO2008151258A2 (en) * 2007-06-04 2008-12-11 Neose Technologies, Inc. O-linked glycosylation using n-acetylglucosaminyl transferases
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
CA2692165A1 (en) * 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
US7968811B2 (en) * 2007-06-29 2011-06-28 Harley-Davidson Motor Company Group, Inc. Integrated ignition and key switch
CL2008002053A1 (es) 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
AR067536A1 (es) 2007-07-17 2009-10-14 Hoffmann La Roche Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea
BRPI0815975B8 (pt) 2007-08-27 2021-05-25 Biogenerix Ag preparação aquosa, recipiente farmacêutico, processo para preparar uma preparação aquosa, e, uso de uma preparação aquosa
US8207112B2 (en) * 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
CN101456911A (zh) * 2007-12-12 2009-06-17 江苏豪森药业股份有限公司 促红细胞生成素模拟肽衍生物及其可药用盐和其制备方法与用途
EP2242505A4 (de) * 2008-01-08 2012-03-07 Biogenerix Ag Glykokonjugation von polypeptiden unter verwendung von oligosaccharyltransferasen
WO2009108806A1 (en) 2008-02-27 2009-09-03 Novo Nordisk A/S Conjugated factor viii molecules
HRP20191109T1 (hr) 2008-08-14 2019-09-20 Acceleron Pharma Inc. Gdf klopke za uporabu u liječenju anemije
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
US20120172299A1 (en) * 2008-09-23 2012-07-05 F. Hoffmann-La Roche Ag Purification of erythropoietin
AU2010258931B2 (en) 2009-06-08 2015-04-23 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
CA2764934A1 (en) 2009-06-24 2010-12-29 F. Hoffmann-La Roche Ag Characterization of re-useable chromatography equipment
BRPI0902481B8 (pt) * 2009-07-31 2021-05-25 Soc Beneficente De Senhoras Hospital Sirio Libanes composição farmacêutica compreendendo hemopressina e seu uso.
KR101882521B1 (ko) * 2009-08-13 2018-07-27 악셀레론 파마 인코포레이티드 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용
WO2011035914A1 (en) * 2009-09-23 2011-03-31 Biogenerix Ag Process for the purification of recombinant human erythropoietin (epo), epo thus purified and pharmaceutical compositions comprising same
CA2781152A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
EP2656063B1 (de) 2010-12-21 2014-10-15 F.Hoffmann-La Roche Ag Chromatografiegerät-charakterisierung
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
CN102816227A (zh) * 2012-08-30 2012-12-12 深圳赛保尔生物药业有限公司 回收促红细胞生成素的方法
ES2884095T3 (es) 2012-11-02 2021-12-10 Celgene Corp Antagonistas de activina-actrii y usos para el tratamiento de trastornos óseos y otros trastornos
CU20140003A7 (es) 2014-01-08 2015-08-27 Ct De Inmunología Molecular Biofarmacuba Conjugado que comprende eritropoyetina y una estructura polimérica ramificada
EP3125922B1 (de) * 2014-03-29 2020-10-14 Intas Pharmaceuticals Limited Flüssige pharmazeutische zusammensetzung von konjugiertem erythropoietin
MA40008A (fr) 2014-06-13 2021-05-05 Acceleron Pharma Inc Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372242A1 (de) 2017-03-06 2018-09-12 Ares Trading S.A. Flüssige pharmazeutische zusammensetzung
EP3372241A1 (de) 2017-03-06 2018-09-12 Ares Trading S.A. Flüssige pharmazeutische zusammensetzung
WO2018184692A1 (en) * 2017-04-07 2018-10-11 Ares Trading S.A. Liquid pharmaceutical composition
PL3731873T3 (pl) * 2017-12-29 2022-04-25 F. Hoffmann-La Roche Ag Sposób dostarczania kompozycji pegylowanego białka
CN111558046A (zh) * 2020-05-27 2020-08-21 华润昂德生物药业有限公司 海藻糖在制备重组人促红素液体制剂中的应用及重组人促红素液体制剂、制备方法和应用
TWI740635B (zh) * 2020-09-09 2021-09-21 財團法人工業技術研究院 聚偏氟乙烯薄膜組成物及聚偏氟乙烯隔離膜

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US147431A (en) * 1874-02-10 Improvement in game boards
US115833A (en) * 1871-06-13 Improvement in grain-driers
JPS6197229A (ja) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US4732889A (en) * 1985-02-06 1988-03-22 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
DE3734923C1 (de) 1987-10-15 1989-01-26 Biotest Pharma Gmbh Verfahren zur Herstellung einer sterilen Plasmaproteinloesung,die Fibrinogen und den Gerinnungsfaktor XIII enthaelt
DE4014654A1 (de) 1990-05-08 1991-11-14 Behringwerke Ag Galenische waessrige formulierungen von erythropoietin und ihre verwendung
JPH05502463A (ja) * 1990-09-28 1993-04-28 オーソ・フアーマシユーチカル・コーポレーシヨン ハイブリツド成長因子
US5272135A (en) 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
NZ244778A (en) 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
US5460944A (en) 1991-10-28 1995-10-24 Boehringer Mannheim Gmbh Storable protein solution
DE4135542A1 (de) 1991-10-28 1993-04-29 Boehringer Mannheim Gmbh Lagerfaehige proteinloesungen
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US5354934A (en) † 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
WO1994028024A1 (en) 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
IL192290A0 (en) * 1993-08-17 2008-12-29 Kirin Amgen Inc Erythropoietin analogs
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
TWI240627B (en) 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
CN100471521C (zh) † 1996-08-02 2009-03-25 奥索·麦克尼尔药品公司 含有与n-末端共价结合的单个水溶性聚合物的多肽类
US5919656A (en) 1996-11-15 1999-07-06 Amgen Canada Inc. Genes encoding telomerase protein 1
EP0885613A1 (de) 1997-06-21 1998-12-23 Roche Diagnostics GmbH Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin
DE19734293A1 (de) 1997-08-08 1999-02-11 Boehringer Mannheim Gmbh Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen
DE69935345T3 (de) 1998-10-23 2018-03-01 Amgen Inc. Methoden und zusammensetzungen zur prävention und behandlung der anämie
UY25790A1 (es) 1998-11-06 2000-08-21 Bio Sidus S A Formas farmaceuticas de eritropoyetina humana recombinante estables a temperatura ambiente y apropiadas para su uso en humanos, formulaciones y procedimientos de liofilizacion para su obtencion.
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
DE60039598D1 (de) 1999-04-09 2008-09-04 Ortho Mcneil Pharm Inc Pharmazeutische zusammensetzungen von erythropoietin
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
PE20010288A1 (es) * 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JP2003517462A (ja) 1999-07-22 2003-05-27 アベンティス・ファーマスーティカルズ・インコーポレイテツド 複数回投与用エリスロポエチン製剤
AU6875900A (en) † 1999-09-08 2001-04-10 Chugai Seiyaku Kabushiki Kaisha Protein solution preparation and method of stabilizing the same
EP1260230A4 (de) 2000-02-29 2008-08-06 Chugai Pharmaceutical Co Ltd Langfristig stabilisierte präparate
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
PT1311285E (pt) * 2000-05-15 2005-06-30 Hoffmann La Roche Composicao farmaceutica liquida contendo um derivado de eritropoietina
WO2002011753A1 (en) † 2000-08-04 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
JP4656814B2 (ja) * 2000-12-20 2011-03-23 エフ．ホフマン−ラ ロシュ アーゲー エリスロポエチンコンジュゲート
US20030104996A1 (en) 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins

Also Published As

Publication number Publication date
CA2408685C (en) 2011-02-01
MEP90708A (hr) 2011-12-20
YU83502A (sh) 2005-11-28
KR20030001509A (ko) 2003-01-06
HUP0302114A2 (hu) 2003-10-28
BR0110914A (pt) 2003-02-11
BRPI0110914B8 (pt) 2021-05-25
TWI288643B (en) 2007-10-21
DE60109625D1 (de) 2005-04-28
US20020037841A1 (en) 2002-03-28
KR20070032815A (ko) 2007-03-22
IL152659A0 (en) 2003-06-24
UY26704A1 (es) 2001-12-28
MA26901A1 (fr) 2004-12-20
WO2001087329A1 (en) 2001-11-22
EP1311285B2 (de) 2017-04-12
HRP20020880A2 (en) 2004-12-31
CN1309416C (zh) 2007-04-11
HRP20020880B1 (en) 2006-04-30
RS51292B (sr) 2010-12-31
SI1311285T1 (de) 2005-08-31
EP1311285B1 (de) 2005-03-23
ES2237574T3 (es) 2005-08-01
PE20020050A1 (es) 2002-02-01
HUP0302114A3 (en) 2012-12-28
NZ522030A (en) 2004-11-26
JO3404B1 (ar) 2019-10-20
AU6593401A (en) 2001-11-26
PL361341A1 (pl) 2004-10-04
PL219131B1 (pl) 2015-03-31
MXPA02011303A (es) 2003-04-25
ES2237574T5 (es) 2017-08-09
JP2003533487A (ja) 2003-11-11
DE60109625T2 (de) 2006-03-30
PT1311285E (pt) 2005-06-30
DE60109625T3 (de) 2017-08-03
ECSP024352A (es) 2003-03-31
CA2408685A1 (en) 2001-11-22
BRPI0110914B1 (pt) 2016-03-01
EP1311285A2 (de) 2003-05-21
DK1311285T4 (en) 2017-07-24
AU784091B2 (en) 2006-02-02
MY128654A (en) 2007-02-28
IL152659A (en) 2010-12-30
TWI288644B (en) 2007-10-21
RU2281116C2 (ru) 2006-08-10
KR100758044B1 (ko) 2007-09-11
ECSP10004352A (es) 2011-01-31
AR092919A2 (es) 2015-05-06
DK1311285T3 (da) 2005-06-27
AR035034A1 (es) 2004-04-14
CN1429116A (zh) 2003-07-09
KR20050121762A (ko) 2005-12-27
ME00673B (me) 2011-12-20
HU230874B1 (hu) 2018-11-29
NO20025450D0 (no) 2002-11-14
US7169754B2 (en) 2007-01-30
CZ20024005A3 (cs) 2004-01-14
US7202208B2 (en) 2007-04-10
NO20025450L (no) 2002-11-14
WO2001087329A8 (en) 2002-03-07
US20040147431A1 (en) 2004-07-29
ZA200208500B (en) 2004-01-28
HK1056683A1 (en) 2004-02-27
JP3967594B2 (ja) 2007-08-29
EP1525889A1 (de) 2005-04-27
CZ304855B6 (cs) 2014-12-10
NO330934B1 (no) 2011-08-22

Similar Documents

Publication Publication Date Title
ATE291436T2 (de) Flüssige arzneizubereitung enthaltend ein erythropoietin derivat
ITTO20010008A0 (it) Formulazione farmaceutica
IS2580B (is) Platínuafleiða lyfjasamsetningar
ATE311915T1 (de) Medikamentenspender
NO20020086L (no) Smaksmaskerte farmasöytiske flytende formuleringer
EP1207512A4 (de) Anzeige
DK1395242T3 (da) Flydende farmaceutisk sammensætning
DK1524266T3 (da) Farmaceutisk sammensætning
EP1207511A4 (de) Anzeige
PT1309317E (pt) Formulacoes farmaceuticas contendo maleato de amlodipina
DE50101916D1 (de) Flüssige formulierungen
NO20026013D0 (no) Medisinske preparater inneholdende propenonderivater
DE60132459D1 (de) Pupillenmesssystem
NO20025081D0 (no) Stabilt flytende preparat
DK1165547T3 (da) Substituerede benzoylpyrazoler som herbicider
DE60028890D1 (de) Flüssigkeitserhitzer
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
ATE312627T1 (de) Lösung enthalend ein oxazolidinone antibiotikum
AR025867A1 (es) Formulacion portasdora farmaceutica
NO20032957D0 (no) Farmasöytisk emulsjonspreparat
EE200300045A (et) Kristalne ravimaine
NO20042074L (no) Makrolider inneholdende farmasoytiske sammensetninger
EP1193107A4 (de) Anzeigegerät
DE69904021D1 (de) Flüsige pharmazeusche zubereitung enthaltend zotepin
DE50105745D1 (de) Anzeigeeinrichtung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1311285

Country of ref document: EP